Courtney Davis
Biographic Data
| ID | 3583590 |
|---|---|
| NAME | Courtney Davis |
| GIVEN NAMES | Courtney |
| FAMILY NAME | Davis |
| SIGNATURE | DAVIS C |
| AFFILIATIONS | University of Sussex |
| ORCID | 0000-0002-9425-9886 |
| VERIFIED | Yes |
| TOTAL WORKS | 18 |
| TOTAL CITATIONS | 83 |
| AUTHOR COUNT | 18 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 1994 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 6 |
The use of adolescent standardized patients to teach psychosocial risk assessment and its impact on medical student self‐efficacy
BACKGROUND: While effective adolescent health care requires clinicians to initiate and navigate conversations about sensitive topics including substance use, sexuality, mood, and safety, trainees frequently report low confidence in addressing these topics. We designed and evaluated a workshop using adolescent standardized patients (ASPs) to improve medical students' self‐efficacy in adolescent communication. METHODS: Graduate medical students on …
Gender-based analysis of body dissatisfaction among youths in Singapore: Findings from the National Youth Mental Health Study
These results emphasize the importance of creating specific public health programs that consider the different experiences and challenges related to body dissatisfaction based on gender. These programs could help promote body image positivity, increase self-compassion, and encourage critical engagement with social media content
International and temporal comparative analysis of UK and US drug safety regulation in changing political contexts
Modern UK drug regulation began in 1971. In view of significant neo-liberal political reforms to drug regulation in the UK and US since the early 1990s, this article compares the performance of UK and US drug safety regulation during both 1971-1992 and 1993-2004, by investigating drug safety withdrawals (DSWs). Combined quantitative and comprehensive qualitative regulatory case history methodology is employed to explain comparative trends in DSWs…
The will of Congress? Permissive regulation and the strategic use of labeling for the anti-influenza drug Relenza
Through an analysis of the FDA's approval of the controversial anti-influenza drug Relenza (zanamivir), we interrogate distinct social scientific theories of pharmaceutical regulation. We investigate why, despite internal negative opinions and an Advisory Committee's non-approval recommendation, the FDA approved Relenza in the late 1990s. Based on a close reading of FDA documents, we show how agency officials guided the manufacturer's analyses an…
Everyday Resistance to Workfare: Welfare Beneficiary Advocacy in Auckland, New Zealand
Beneficiary advocacy organisations, which provide advice to individual claimants about how best to navigate the welfare system, exist in the context of complex and opaque benefit-claiming processes that have resulted from workfare policies. Drawing on a case study of Auckland Action Against Poverty, an organisation specialising in poverty activism and services for welfare beneficiaries, this article examines the provision of beneficiary advocacy …
Clarity, constructive debate and progress in developing methodological and conceptual frameworks for understanding pharmaceuticalization: A reply to Abraham
Drugs, cancer and end-of-life care: A case study of pharmaceuticalization
The political dynamics of citizenship, innovation, and regulation in pharmaceutical governance
This article provides an analysis of the regulation of innovative pharmaceuticals in the EU and the United States, particularly fast-track or accelerated review and marketing approval mechanisms therein since 1995. Specifically, consideration is given to whether that regulation is best characterized by “disease politics”, “pluralist” pressure politics, “corporatist” partnership with industry, “clientele pluralism” leading to industrial capture of…
A comparative analysis of risk management strategies in European Union and United States pharmaceutical regulation
Analyses of risk management within prescription pharmaceutical regulation are rare. We present the first comparison of pharmaceutical risk regulation between the EU's centralised supranational ‘state’ and another country, the US. Drawing on documentary and interview-based research on case-study drugs and risk management, we argue that ‘risk colonisation’, neo-liberal governmentality, and pressure from powerful industry interests have combined to …
The socio-political roots of pharmaceutical uncertainty in the evaluation of ‘innovative’ diabetes drugs in the European Union and the US
Desperately seeking cancer drugs: Explaining the Emergence and Outcomes of Accelerated Pharmaceutical Regulation
Government regulators have increasingly accelerated new cancer drugs on to the market by granting them approval based on less clinical data supporting drug efficacy than permitted under standard regulations. With more lenient regulatory standards, pharmaceutical companies have keenly sought to develop cancer drugs. Focusing on the US, this article examines how the emergence and implementation of such accelerated approvals should be understood, pa…
Drug Evaluation and the Permissive Principle: Continuities and Contradictions between Standards and Practices in Antidepressant Regulation
Pharmaceuticals are not permitted on to the market unless they are granted regulatory approval. The regulatory process is, therefore, crucial in whether or not a drug is widely prescribed. Regulatory agencies have developed standards of performance that pharmaceuticals are supposed to meet before entering the market. Regulation of technologies is often discussed by reference to the precautionary principle. In contrast, this paper develops the con…
Deficits, Expectations and Paradigms in British and American Drug Safety Assessments: Prising Open the Black Box of Regulatory Science
This article examines the regulation of nonsteroidal anti-inflammatory drugs (NSAIDs), with particular focus on products approved for marketing in the United Kingdom, while denied marketing approval in the United States on safety grounds, and then subsequently withdrawn from the UK market on those grounds. Using international comparison of regulatory data never before accessed outside government and companies, together with interviews with releva…
Testing Times: The Emergence of the Practolol Disaster and its Challenge to British Drug Regulation in the Modern Period
This article analyses how practolol, the first British drug disaster of the modern, post-thalidomide regulatory period, related to the pharmaceutical industry, the medical profession and government regulation of patients' health. Drawing on comparison with the USA, it argues that, contrary to public expectation and perception, the aftermath of thalidomide did not give rise to strident British drug control, imposing the highest possible safety sta…
Risking public safety: Experts, the medical profession and ‘acceptable’ drug injury
By locating expertise within an institutional framework, this paper examines the roles of regulators, the pharmaceutical industry and the medical profession in drug risk assessment and in the construction of ‘acceptable’ drug injury in particular. It is suggested that, while public perceptions of risks are important, they may be extremely limited due to relative secrecy surrounding some risk-generating activities, such as pharmaceutical developme…
A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): Implications for current regulatory thinking and policy
African American Student Teachers' Perceptions About Preparedness to Teach Students From Culturally and Linguistically Diverse Backgrounds
(2002). African American Student Teachers' Perceptions About Preparedness to Teach Students From Culturally and Linguistically Diverse Backgrounds. Multicultural Perspectives: Vol. 4, No. 1, pp. 18-25
The Art of Celtia
A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): Implications for current regulatory thinking and policy
Drug Evaluation and the Permissive Principle: Continuities and Contradictions between Standards and Practices in Antidepressant Regulation
Pharmaceuticals are not permitted on to the market unless they are granted regulatory approval. The regulatory process is, therefore, crucial in whether or not a drug is widely prescribed. Regulatory agencies have developed standards of performance that pharmaceuticals are supposed to meet before entering the market. Regulation of technologies is often discussed by reference to the precautionary principle. In contrast, this paper develops the con…
Desperately seeking cancer drugs: Explaining the Emergence and Outcomes of Accelerated Pharmaceutical Regulation
Government regulators have increasingly accelerated new cancer drugs on to the market by granting them approval based on less clinical data supporting drug efficacy than permitted under standard regulations. With more lenient regulatory standards, pharmaceutical companies have keenly sought to develop cancer drugs. Focusing on the US, this article examines how the emergence and implementation of such accelerated approvals should be understood, pa…
Drugs, cancer and end-of-life care: A case study of pharmaceuticalization
Deficits, Expectations and Paradigms in British and American Drug Safety Assessments: Prising Open the Black Box of Regulatory Science
This article examines the regulation of nonsteroidal anti-inflammatory drugs (NSAIDs), with particular focus on products approved for marketing in the United Kingdom, while denied marketing approval in the United States on safety grounds, and then subsequently withdrawn from the UK market on those grounds. Using international comparison of regulatory data never before accessed outside government and companies, together with interviews with releva…
Everyday Resistance to Workfare: Welfare Beneficiary Advocacy in Auckland, New Zealand
Beneficiary advocacy organisations, which provide advice to individual claimants about how best to navigate the welfare system, exist in the context of complex and opaque benefit-claiming processes that have resulted from workfare policies. Drawing on a case study of Auckland Action Against Poverty, an organisation specialising in poverty activism and services for welfare beneficiaries, this article examines the provision of beneficiary advocacy …
International and temporal comparative analysis of UK and US drug safety regulation in changing political contexts
Modern UK drug regulation began in 1971. In view of significant neo-liberal political reforms to drug regulation in the UK and US since the early 1990s, this article compares the performance of UK and US drug safety regulation during both 1971-1992 and 1993-2004, by investigating drug safety withdrawals (DSWs). Combined quantitative and comprehensive qualitative regulatory case history methodology is employed to explain comparative trends in DSWs…
Testing Times: The Emergence of the Practolol Disaster and its Challenge to British Drug Regulation in the Modern Period
This article analyses how practolol, the first British drug disaster of the modern, post-thalidomide regulatory period, related to the pharmaceutical industry, the medical profession and government regulation of patients' health. Drawing on comparison with the USA, it argues that, contrary to public expectation and perception, the aftermath of thalidomide did not give rise to strident British drug control, imposing the highest possible safety sta…
The will of Congress? Permissive regulation and the strategic use of labeling for the anti-influenza drug Relenza
Through an analysis of the FDA's approval of the controversial anti-influenza drug Relenza (zanamivir), we interrogate distinct social scientific theories of pharmaceutical regulation. We investigate why, despite internal negative opinions and an Advisory Committee's non-approval recommendation, the FDA approved Relenza in the late 1990s. Based on a close reading of FDA documents, we show how agency officials guided the manufacturer's analyses an…
The socio-political roots of pharmaceutical uncertainty in the evaluation of ‘innovative’ diabetes drugs in the European Union and the US
African American Student Teachers' Perceptions About Preparedness to Teach Students From Culturally and Linguistically Diverse Backgrounds
(2002). African American Student Teachers' Perceptions About Preparedness to Teach Students From Culturally and Linguistically Diverse Backgrounds. Multicultural Perspectives: Vol. 4, No. 1, pp. 18-25
The Art of Celtia
African American Student Teachers' Perceptions About Preparedness to Teach Students From Culturally and Linguistically Diverse Backgrounds
(2002). African American Student Teachers' Perceptions About Preparedness to Teach Students From Culturally and Linguistically Diverse Backgrounds. Multicultural Perspectives: Vol. 4, No. 1, pp. 18-25
Risking public safety: Experts, the medical profession and ‘acceptable’ drug injury
By locating expertise within an institutional framework, this paper examines the roles of regulators, the pharmaceutical industry and the medical profession in drug risk assessment and in the construction of ‘acceptable’ drug injury in particular. It is suggested that, while public perceptions of risks are important, they may be extremely limited due to relative secrecy surrounding some risk-generating activities, such as pharmaceutical developme…
A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): Implications for current regulatory thinking and policy
Testing Times: The Emergence of the Practolol Disaster and its Challenge to British Drug Regulation in the Modern Period
This article analyses how practolol, the first British drug disaster of the modern, post-thalidomide regulatory period, related to the pharmaceutical industry, the medical profession and government regulation of patients' health. Drawing on comparison with the USA, it argues that, contrary to public expectation and perception, the aftermath of thalidomide did not give rise to strident British drug control, imposing the highest possible safety sta…
Deficits, Expectations and Paradigms in British and American Drug Safety Assessments: Prising Open the Black Box of Regulatory Science
This article examines the regulation of nonsteroidal anti-inflammatory drugs (NSAIDs), with particular focus on products approved for marketing in the United Kingdom, while denied marketing approval in the United States on safety grounds, and then subsequently withdrawn from the UK market on those grounds. Using international comparison of regulatory data never before accessed outside government and companies, together with interviews with releva…
Drug Evaluation and the Permissive Principle: Continuities and Contradictions between Standards and Practices in Antidepressant Regulation
Pharmaceuticals are not permitted on to the market unless they are granted regulatory approval. The regulatory process is, therefore, crucial in whether or not a drug is widely prescribed. Regulatory agencies have developed standards of performance that pharmaceuticals are supposed to meet before entering the market. Regulation of technologies is often discussed by reference to the precautionary principle. In contrast, this paper develops the con…
A comparative analysis of risk management strategies in European Union and United States pharmaceutical regulation
Analyses of risk management within prescription pharmaceutical regulation are rare. We present the first comparison of pharmaceutical risk regulation between the EU's centralised supranational ‘state’ and another country, the US. Drawing on documentary and interview-based research on case-study drugs and risk management, we argue that ‘risk colonisation’, neo-liberal governmentality, and pressure from powerful industry interests have combined to …
The socio-political roots of pharmaceutical uncertainty in the evaluation of ‘innovative’ diabetes drugs in the European Union and the US
Desperately seeking cancer drugs: Explaining the Emergence and Outcomes of Accelerated Pharmaceutical Regulation
Government regulators have increasingly accelerated new cancer drugs on to the market by granting them approval based on less clinical data supporting drug efficacy than permitted under standard regulations. With more lenient regulatory standards, pharmaceutical companies have keenly sought to develop cancer drugs. Focusing on the US, this article examines how the emergence and implementation of such accelerated approvals should be understood, pa…
The political dynamics of citizenship, innovation, and regulation in pharmaceutical governance
This article provides an analysis of the regulation of innovative pharmaceuticals in the EU and the United States, particularly fast-track or accelerated review and marketing approval mechanisms therein since 1995. Specifically, consideration is given to whether that regulation is best characterized by “disease politics”, “pluralist” pressure politics, “corporatist” partnership with industry, “clientele pluralism” leading to industrial capture of…
Clarity, constructive debate and progress in developing methodological and conceptual frameworks for understanding pharmaceuticalization: A reply to Abraham
Drugs, cancer and end-of-life care: A case study of pharmaceuticalization
Everyday Resistance to Workfare: Welfare Beneficiary Advocacy in Auckland, New Zealand
Beneficiary advocacy organisations, which provide advice to individual claimants about how best to navigate the welfare system, exist in the context of complex and opaque benefit-claiming processes that have resulted from workfare policies. Drawing on a case study of Auckland Action Against Poverty, an organisation specialising in poverty activism and services for welfare beneficiaries, this article examines the provision of beneficiary advocacy …
The will of Congress? Permissive regulation and the strategic use of labeling for the anti-influenza drug Relenza
Through an analysis of the FDA's approval of the controversial anti-influenza drug Relenza (zanamivir), we interrogate distinct social scientific theories of pharmaceutical regulation. We investigate why, despite internal negative opinions and an Advisory Committee's non-approval recommendation, the FDA approved Relenza in the late 1990s. Based on a close reading of FDA documents, we show how agency officials guided the manufacturer's analyses an…
International and temporal comparative analysis of UK and US drug safety regulation in changing political contexts
Modern UK drug regulation began in 1971. In view of significant neo-liberal political reforms to drug regulation in the UK and US since the early 1990s, this article compares the performance of UK and US drug safety regulation during both 1971-1992 and 1993-2004, by investigating drug safety withdrawals (DSWs). Combined quantitative and comprehensive qualitative regulatory case history methodology is employed to explain comparative trends in DSWs…
Gender-based analysis of body dissatisfaction among youths in Singapore: Findings from the National Youth Mental Health Study
These results emphasize the importance of creating specific public health programs that consider the different experiences and challenges related to body dissatisfaction based on gender. These programs could help promote body image positivity, increase self-compassion, and encourage critical engagement with social media content
The use of adolescent standardized patients to teach psychosocial risk assessment and its impact on medical student self‐efficacy
BACKGROUND: While effective adolescent health care requires clinicians to initiate and navigate conversations about sensitive topics including substance use, sexuality, mood, and safety, trainees frequently report low confidence in addressing these topics. We designed and evaluated a workshop using adolescent standardized patients (ASPs) to improve medical students' self‐efficacy in adolescent communication. METHODS: Graduate medical students on …
Political science (15 works) · Medicine (12 works) · Economics (10 works) · Pharmaceutical industry and healthcare (10 works) · Law (9 works) · Law (8 works) · Pharmaceutical industry (8 works) · Pharmacology (8 works) · Business (7 works) · Pharmaceutical Economics and Policy (7 works)